A growing arsenal of non-insulin diabetes medications is expanding therapeutic options beyond traditional insulin therapy. GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated significant benefits in glycemic control while reducing cardiovascular risks. DPP-4 inhibitors offer a convenient oral alternative, particularly for patients seeking weight-neutral treatments. Recent advancements include combination therapies that target multiple metabolic pathways simultaneously, enhancing efficacy while minimizing side effects. Additionally, bile acid sequestrants, dopamine agonists, and amylin analogs provide novel mechanisms for improving insulin sensitivity. With continued research into incretin-based therapies and dual-agonist formulations, non-insulin medications are playing a crucial role in personalized diabetes management.
Title : Diabetes reduction (pre-diabetes and type 2) with integrative medicine
F Buck Willis, IUHS School of Medicine, Saint Kitts and Nevis
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters?
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : Clinical applications of monitoring unmethylated insulin cfDNA associated with beta-cell death for diabetes and metabolic diseases
Clifford Morris, Kihealth, United States
Title : Diabetes and migration: Impact of internal displacement on the prevalence and management of diabetes in Les Cayes, South Haiti (2022-2024)
Berger Saintius, Field Epidemiology Training Program (FETP), Haiti
Title : Correlation between food insecurity and diabetes in the commune of Les Cayes (2021-2024)
Djeamsly Salomon, Field Epidemiology Training Program (FETP), Haiti